EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of a novel natural compound inhibitor targeting AmpC β-lactamase to combat multidrug-resistant Pseudomonas aeruginosa

Santhosh Mudipalli Elavarasu, Sasikumar K

Frontiers in Microbiology · 19.05.2026 · 17

DOI: 10.3389/fmicb.2026.1813201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 19.05.2026. Verfasst von Santhosh Mudipalli Elavarasu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Biology, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, India. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Antimicrobial resistance (AMR) remains one of the most urgent threats to global public health, driven by the rising prevalence of multidrug-resistant (MDR) pathogens such as Pseudomonas aeruginosa. A key mediator of resistance in this organism is AmpC β-lactamase, an enzyme that confers bacterial survival by hydrolysing β-lactam antibiotics before they can exert their effect.

Methods

We screened 374 compounds from the ChemDiv chemical library for novel inhibitors that target this enzyme, with a bias toward natural-compound-derived scaffolds as an alternative to existing resistance-countering strategies. Pharmacokinetic profiling was performed using SwissADME. Molecular dynamics (MD) simulations were carried out to further characterize the stability of the protein-ligand complex. Additionally, free energy perturbation (FEP) calculations were performed to quantitatively verify the binding affinity towards AmpC β-lactamase.

Results

Among the screened compounds, compound N094-0017 emerged as the top candidate. It showed good affinity for the AmpC active site and formed stable hydrogen bonds, with a binding energy of −5.6 kcal/mol. SwissADME-based pharmacokinetic profiling suggested desirable drug-like and favourable oral bioavailability profiles. MD simulations were conducted to further characterize the stability of the protein-ligand complex, and the RMSD, RMSF, and SASA profiles were consistent, confirming stable retention of the ligand within the active site throughout the simulation period. Moreover, FEP calculations showed a binding free energy of ∼40 kJ/mol for N094-0017 toward AmpC β-lactamase.

Discussion

In conclusion, these data suggest N094-0017 as a promising candidate for an AmpC β-lactamase inhibitor, and natural compounds present a promising strategy for addressing the growing challenge of AMR.

Schlagwörter

Stichwörter der Autor:innen

AmpC β-lactamasePseudomonas aeruginosaantimicrobial resistancemolecular dynamicsvirtual screening

Autor:innen und Institutionen

  • Department of Integrative Biology, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, India.
  • Department of Sensor and Biomedical Technology, School of Electronics Engineering, Vellore Institute of Technology (VIT), Vellore, India.

Zitieren

APA

Mudipalli Elavarasu, S., & K, S. (2026). Identification of a novel natural compound inhibitor targeting AmpC β-lactamase to combat multidrug-resistant Pseudomonas aeruginosa. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1813201

Vancouver

Mudipalli Elavarasu S, K S. Identification of a novel natural compound inhibitor targeting AmpC β-lactamase to combat multidrug-resistant Pseudomonas aeruginosa. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1813201

BibTeX
@article{MudipalliElavarasu2026,
  author = {Mudipalli Elavarasu, Santhosh and K, Sasikumar},
  title = {Identification of a novel natural compound inhibitor targeting AmpC β-lactamase to combat multidrug-resistant Pseudomonas aeruginosa},
  journal = {Frontiers in Microbiology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fmicb.2026.1813201}
}
Kostenlos starten →